United Therapeutics Corporation reported third-quarter 2026 total revenues of $832.5 million, a 4% increase year-over-year, driven by higher sales of Tyvaso DPI and Orenitram. However, net income decreased to $258.6 million, down from $338.7 million in the third quarter of 2025, largely due to increased research and development expenses associated with the Thymmune acquisition.
Total revenues for the quarter ended September 30, 2026, rose 4% to $832.5 million compared to $799.5 million for the same period in 2025.
Net income declined 24% to $258.6 million, or $5.71 per diluted share, compared to $338.7 million, or $7.16 per diluted share, in the third quarter of 2025.
Research and development expenses increased 119% to $279.2 million, driven by the acquisition of Thymmune Therapeutics, Inc. and ongoing organ alternative projects.
The board approved a new share repurchase program in October 2026 authorizing up to $2.0 billion in aggregate repurchases through October 21, 2027.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From United Therapeutics's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$3.18B
+10.6%
$27.86
+13.1%
41.9%
FY2024
$2.88B
+23.6%
$24.64
+24.4%
41.5%
FY2023
$2.33B
+20.2%
$19.81
+32.1%
42.3%
FY2022
$1.94B
+14.9%
$15.00
+49.1%
37.6%
FY2021
$1.69B
+13.6%
$10.06
-12.8%
28.2%
Frequently asked questions
When is United Therapeutics's next earnings date?
United Therapeutics has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did United Therapeutics earn last quarter?
For the quarter ended Sep 2026, United Therapeutics reported diluted EPS of $5.71 (-20.3% year over year) on revenue of $832.50M (+4.1%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.